114 related articles for article (PubMed ID: 20224944)
1. Superior efficacy of new medicines?
van Luijn JC; Gribnau FW; Leufkens HG
Eur J Clin Pharmacol; 2010 May; 66(5):445-8. PubMed ID: 20224944
[TBL] [Abstract][Full Text] [Related]
2. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
3. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
4. Availability of comparative trials for the assessment of new medicines in the European Union at the moment of market authorization.
van Luijn JC; Gribnau FW; Leufkens HG
Br J Clin Pharmacol; 2007 Feb; 63(2):159-62. PubMed ID: 17166187
[TBL] [Abstract][Full Text] [Related]
5. Choice of comparator in active control trials of new drugs.
van Luijn JC; van Loenen AC; Gribnau FW; Leufkens HG
Ann Pharmacother; 2008 Nov; 42(11):1605-12. PubMed ID: 18957629
[TBL] [Abstract][Full Text] [Related]
6. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
7. The European Regulation on medicines for paediatric use.
Dunne J
Paediatr Respir Rev; 2007 Jun; 8(2):177-83. PubMed ID: 17574163
[TBL] [Abstract][Full Text] [Related]
8. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
[TBL] [Abstract][Full Text] [Related]
9. [Controlled randomized clinical trials].
Jaillon P
Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
[TBL] [Abstract][Full Text] [Related]
10. The review of drug applications submitted to the European Medicines Evaluation Agency: frequently raised objections, and outcome.
Pignatti F; Aronsson B; Gate N; Vamvakas S; Wade G; Moulon I; Le Courtois P
Eur J Clin Pharmacol; 2002 Dec; 58(9):573-80. PubMed ID: 12525957
[TBL] [Abstract][Full Text] [Related]
11. Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?
Carroll KJ
Pharm Stat; 2006; 5(4):283-93. PubMed ID: 17128427
[TBL] [Abstract][Full Text] [Related]
12. A decision rule for sequential monitoring of clinical trials with a primary and supportive outcome.
Zhao Y; Grambsch PM; Neaton JD
Clin Trials; 2007; 4(2):140-53. PubMed ID: 17456513
[TBL] [Abstract][Full Text] [Related]
13. Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations.
Merli G; Spyropoulos AC; Caprini JA
Ann Surg; 2009 Aug; 250(2):219-28. PubMed ID: 19638915
[TBL] [Abstract][Full Text] [Related]
14. Trends in risks associated with new drug development: success rates for investigational drugs.
DiMasi JA; Feldman L; Seckler A; Wilson A
Clin Pharmacol Ther; 2010 Mar; 87(3):272-7. PubMed ID: 20130567
[TBL] [Abstract][Full Text] [Related]
15. New antibiotics for paediatric use: a review of a decade of regulatory trials submitted to the European Medicines Agency from 2000--why aren't we doing better?
Garazzino S; Lutsar I; Bertaina C; Tovo PA; Sharland M
Int J Antimicrob Agents; 2013 Aug; 42(2):99-118. PubMed ID: 23810180
[TBL] [Abstract][Full Text] [Related]
16. [HTA-Perspective: Challenges in the early assessment of new oncological drugs].
Wild C; Nachtnebel A
Z Evid Fortbild Qual Gesundhwes; 2013; 107(2):129-35. PubMed ID: 23663907
[TBL] [Abstract][Full Text] [Related]
17. New pathway for qualification of novel methodologies in the European Medicines Agency.
Manolis E; Vamvakas S; Isaac M
Proteomics Clin Appl; 2011 Jun; 5(5-6):248-55. PubMed ID: 21538915
[TBL] [Abstract][Full Text] [Related]
18. Medicines discovery in the 21st century: the case for a stakeholder corporation.
Dixon J; England P; Lawton G; Machin P; Palmer A
Drug Discov Today; 2010 Sep; 15(17-18):700-3. PubMed ID: 20678583
[TBL] [Abstract][Full Text] [Related]
19. State of the art in benefit-risk analysis: medicines.
Luteijn JM; White BC; Gunnlaugsdóttir H; Holm F; Kalogeras N; Leino O; Magnússon SH; Odekerken G; Pohjola MV; Tijhuis MJ; Tuomisto JT; Ueland Ø; McCarron PA; Verhagen H
Food Chem Toxicol; 2012 Jan; 50(1):26-32. PubMed ID: 21683115
[TBL] [Abstract][Full Text] [Related]
20. Colorectal and gastric cancer in 2015: The development of new agents and molecular classifications.
Van Cutsem E; Ducreux M
Nat Rev Clin Oncol; 2016 Feb; 13(2):69-70. PubMed ID: 26667973
[No Abstract] [Full Text] [Related]
[Next] [New Search]
